Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors—Are We Really Safer Now?
A partir d'une revue systématique de la littérature publiée jusqu'en mars 2020 (39 essais incluant un total de 23 705 patients), cette méta-analyse évalue l'association entre une utilisation d'inhibiteurs de points de contrôle immunitaire et la survenue d'événements indésirables de nature neurologique chez des patients atteints d'un cancer
More than a decade from the first US Food and Drug Administration (FDA) approval of an immune checkpoint inhibitor (ICI) for treatment of cancer,1 prompt identification and management of immune-related adverse events (IRAEs) remain challenges faced in clinical practice daily. This systematic review and meta-analysis by Farooq and colleagues,2 assesses the risks of neurological adverse events (NAEs) during treatment with ICIs compared with control groups of randomized studies, including placebo and active treatments, such as chemotherapy and targeted therapies.
JAMA Network Open , commentaire en libre accès, 2021